Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pleural Neoplasms | 21 | 2021 | 609 | 1.910 |
Why?
|
Mesothelioma | 21 | 2021 | 807 | 1.650 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 49 | 2024 | 5315 | 1.610 |
Why?
|
Lung Neoplasms | 65 | 2024 | 13380 | 1.510 |
Why?
|
Medulloblastoma | 10 | 2022 | 678 | 0.980 |
Why?
|
Cerebellar Neoplasms | 9 | 2022 | 586 | 0.900 |
Why?
|
Photons | 9 | 2020 | 589 | 0.870 |
Why?
|
Brain Neoplasms | 18 | 2024 | 9031 | 0.650 |
Why?
|
Protein Kinase Inhibitors | 26 | 2024 | 5671 | 0.610 |
Why?
|
Adenocarcinoma | 19 | 2022 | 6346 | 0.570 |
Why?
|
Quinazolines | 17 | 2012 | 1371 | 0.570 |
Why?
|
Neoplasm Recurrence, Local | 25 | 2022 | 9280 | 0.480 |
Why?
|
Drug Resistance, Neoplasm | 17 | 2024 | 5305 | 0.460 |
Why?
|
Pneumonectomy | 8 | 2021 | 1119 | 0.420 |
Why?
|
Propensity Score | 1 | 2020 | 1913 | 0.410 |
Why?
|
Receptor Protein-Tyrosine Kinases | 10 | 2019 | 1626 | 0.400 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 30 | 2024 | 11742 | 0.400 |
Why?
|
Neoplasm Staging | 33 | 2021 | 11121 | 0.380 |
Why?
|
Aminopyridines | 4 | 2022 | 573 | 0.370 |
Why?
|
Ependymoma | 5 | 2021 | 320 | 0.360 |
Why?
|
Pancreatic Neoplasms | 8 | 2022 | 5368 | 0.340 |
Why?
|
Radiotherapy Dosage | 16 | 2024 | 2898 | 0.340 |
Why?
|
Antineoplastic Agents | 25 | 2018 | 13639 | 0.340 |
Why?
|
Protons | 9 | 2024 | 1116 | 0.340 |
Why?
|
Relative Biological Effectiveness | 8 | 2020 | 312 | 0.330 |
Why?
|
Mutation | 35 | 2024 | 30052 | 0.310 |
Why?
|
Neoadjuvant Therapy | 9 | 2021 | 2827 | 0.310 |
Why?
|
Pyrazoles | 7 | 2022 | 2009 | 0.300 |
Why?
|
Radiotherapy, Conformal | 6 | 2018 | 548 | 0.290 |
Why?
|
Radiodermatitis | 3 | 2019 | 60 | 0.290 |
Why?
|
Prognosis | 37 | 2021 | 29625 | 0.290 |
Why?
|
Fluorouracil | 6 | 2021 | 1641 | 0.290 |
Why?
|
Central Nervous System Neoplasms | 5 | 2020 | 916 | 0.290 |
Why?
|
Glioma | 4 | 2019 | 3455 | 0.290 |
Why?
|
Carbazoles | 2 | 2018 | 220 | 0.280 |
Why?
|
Radiation Injuries | 4 | 2019 | 1189 | 0.270 |
Why?
|
Gene Amplification | 5 | 2020 | 1089 | 0.270 |
Why?
|
Cranial Irradiation | 3 | 2022 | 390 | 0.270 |
Why?
|
Middle Aged | 114 | 2023 | 220895 | 0.270 |
Why?
|
Aged, 80 and over | 60 | 2021 | 58976 | 0.270 |
Why?
|
Cholangiocarcinoma | 3 | 2018 | 552 | 0.270 |
Why?
|
Humans | 191 | 2024 | 761504 | 0.270 |
Why?
|
Lactams, Macrocyclic | 3 | 2022 | 318 | 0.260 |
Why?
|
Lactams | 3 | 2022 | 156 | 0.260 |
Why?
|
Oncogene Proteins, Fusion | 4 | 2021 | 1606 | 0.260 |
Why?
|
Cord Blood Stem Cell Transplantation | 4 | 2010 | 305 | 0.260 |
Why?
|
Carboplatin | 4 | 2021 | 794 | 0.260 |
Why?
|
Male | 133 | 2024 | 360804 | 0.250 |
Why?
|
Female | 139 | 2024 | 392644 | 0.250 |
Why?
|
Aged | 98 | 2021 | 169289 | 0.250 |
Why?
|
Radiosurgery | 3 | 2022 | 1342 | 0.250 |
Why?
|
Cisplatin | 9 | 2013 | 1651 | 0.250 |
Why?
|
Carcinoma, Hepatocellular | 5 | 2020 | 2298 | 0.250 |
Why?
|
Liver Neoplasms | 6 | 2020 | 4320 | 0.240 |
Why?
|
Kaplan-Meier Estimate | 18 | 2020 | 6484 | 0.240 |
Why?
|
Adult | 99 | 2024 | 221177 | 0.240 |
Why?
|
Transplantation Conditioning | 6 | 2014 | 1590 | 0.230 |
Why?
|
Radiotherapy, Adjuvant | 9 | 2022 | 1784 | 0.230 |
Why?
|
Survival Rate | 29 | 2020 | 12725 | 0.230 |
Why?
|
Proto-Oncogene Proteins | 7 | 2021 | 4511 | 0.230 |
Why?
|
Brain Stem | 3 | 2022 | 858 | 0.220 |
Why?
|
Radium | 1 | 2024 | 72 | 0.220 |
Why?
|
Lymphoma, Non-Hodgkin | 8 | 2013 | 1374 | 0.220 |
Why?
|
Proto-Oncogene Proteins c-met | 3 | 2020 | 571 | 0.210 |
Why?
|
Bone Marrow Transplantation | 8 | 2011 | 2693 | 0.200 |
Why?
|
Fibromatosis, Aggressive | 2 | 2013 | 126 | 0.190 |
Why?
|
Retrospective Studies | 44 | 2022 | 80636 | 0.190 |
Why?
|
Cytidine Deaminase | 1 | 2023 | 243 | 0.190 |
Why?
|
Olfaction Disorders | 1 | 2024 | 224 | 0.190 |
Why?
|
Disease-Free Survival | 13 | 2017 | 6814 | 0.190 |
Why?
|
Sarcoma | 4 | 2014 | 1801 | 0.190 |
Why?
|
Retinoblastoma | 2 | 2014 | 317 | 0.190 |
Why?
|
Radiotherapy | 5 | 2021 | 1499 | 0.190 |
Why?
|
Hypopituitarism | 1 | 2023 | 250 | 0.190 |
Why?
|
Cognition | 2 | 2018 | 6990 | 0.190 |
Why?
|
Combined Modality Therapy | 19 | 2022 | 8529 | 0.180 |
Why?
|
Treatment Outcome | 38 | 2023 | 64680 | 0.180 |
Why?
|
ras Proteins | 5 | 2014 | 1054 | 0.180 |
Why?
|
Gene Rearrangement | 4 | 2018 | 1125 | 0.180 |
Why?
|
Prospective Studies | 22 | 2024 | 54425 | 0.180 |
Why?
|
Piperidines | 3 | 2018 | 1656 | 0.180 |
Why?
|
Carcinoma, Pancreatic Ductal | 3 | 2021 | 1727 | 0.180 |
Why?
|
Survival Analysis | 20 | 2019 | 10090 | 0.180 |
Why?
|
Physicians, Women | 2 | 2024 | 508 | 0.170 |
Why?
|
Young Adult | 33 | 2024 | 59243 | 0.170 |
Why?
|
Graft vs Leukemia Effect | 2 | 2011 | 121 | 0.170 |
Why?
|
Pyridines | 5 | 2020 | 2875 | 0.170 |
Why?
|
Protein-Tyrosine Kinases | 5 | 2021 | 2425 | 0.170 |
Why?
|
Phospholipase D | 1 | 2019 | 67 | 0.170 |
Why?
|
Chemotherapy, Adjuvant | 6 | 2015 | 3514 | 0.170 |
Why?
|
Neuroectodermal Tumors, Primitive | 1 | 2020 | 136 | 0.160 |
Why?
|
Infratentorial Neoplasms | 2 | 2017 | 98 | 0.160 |
Why?
|
Pituitary Neoplasms | 2 | 2023 | 1324 | 0.160 |
Why?
|
Bile Duct Neoplasms | 2 | 2015 | 605 | 0.160 |
Why?
|
Follow-Up Studies | 27 | 2022 | 39106 | 0.160 |
Why?
|
Congresses as Topic | 1 | 2024 | 803 | 0.160 |
Why?
|
Lymphopenia | 1 | 2021 | 281 | 0.160 |
Why?
|
Radiotherapy, Intensity-Modulated | 2 | 2022 | 801 | 0.160 |
Why?
|
Molecular Targeted Therapy | 5 | 2023 | 2811 | 0.150 |
Why?
|
Nonlinear Dynamics | 1 | 2001 | 492 | 0.150 |
Why?
|
Bilirubin | 1 | 2020 | 436 | 0.150 |
Why?
|
Platinum | 1 | 2019 | 220 | 0.150 |
Why?
|
Neuroma, Acoustic | 1 | 2022 | 459 | 0.150 |
Why?
|
Carcinoma, Merkel Cell | 2 | 2012 | 328 | 0.150 |
Why?
|
Radiation Oncology | 1 | 2024 | 563 | 0.150 |
Why?
|
Deoxycytidine | 2 | 2014 | 877 | 0.150 |
Why?
|
Neurosecretory Systems | 1 | 2019 | 223 | 0.150 |
Why?
|
Radiation-Sensitizing Agents | 2 | 2021 | 350 | 0.150 |
Why?
|
Biometry | 1 | 2001 | 563 | 0.150 |
Why?
|
Breast Neoplasms | 7 | 2021 | 21012 | 0.150 |
Why?
|
Hematopoietic Stem Cell Transplantation | 6 | 2014 | 5671 | 0.150 |
Why?
|
Wechsler Scales | 1 | 2018 | 257 | 0.150 |
Why?
|
Losartan | 1 | 2019 | 265 | 0.140 |
Why?
|
Gene Expression Profiling | 6 | 2016 | 9420 | 0.140 |
Why?
|
Intraoperative Care | 2 | 2013 | 767 | 0.140 |
Why?
|
Ubiquitin Thiolesterase | 1 | 2020 | 455 | 0.140 |
Why?
|
Graft vs Host Disease | 6 | 2014 | 3029 | 0.140 |
Why?
|
Proto-Oncogene Proteins B-raf | 3 | 2018 | 2057 | 0.140 |
Why?
|
Organophosphorus Compounds | 1 | 2018 | 206 | 0.140 |
Why?
|
Serum Albumin | 1 | 2020 | 672 | 0.140 |
Why?
|
Hematologic Diseases | 1 | 2020 | 496 | 0.140 |
Why?
|
Liver Failure | 1 | 2019 | 250 | 0.140 |
Why?
|
Societies, Medical | 3 | 2024 | 3905 | 0.140 |
Why?
|
DNA Mutational Analysis | 7 | 2020 | 4111 | 0.140 |
Why?
|
In Situ Hybridization, Fluorescence | 9 | 2013 | 2510 | 0.130 |
Why?
|
Child, Preschool | 22 | 2024 | 42230 | 0.130 |
Why?
|
Inhibitor of Apoptosis Proteins | 2 | 2007 | 197 | 0.130 |
Why?
|
Hyperthermia, Induced | 2 | 2013 | 417 | 0.130 |
Why?
|
Immunity, Humoral | 2 | 2010 | 606 | 0.130 |
Why?
|
Pulmonary Fibrosis | 2 | 2018 | 505 | 0.130 |
Why?
|
Anus Neoplasms | 1 | 2019 | 329 | 0.120 |
Why?
|
Meningeal Neoplasms | 2 | 2017 | 1248 | 0.120 |
Why?
|
Adolescent | 32 | 2024 | 88319 | 0.120 |
Why?
|
Histocompatibility | 2 | 2009 | 317 | 0.120 |
Why?
|
Rhabdoid Tumor | 2 | 2017 | 210 | 0.120 |
Why?
|
Spinal Neoplasms | 2 | 2014 | 716 | 0.120 |
Why?
|
Dihydrotestosterone | 1 | 2015 | 195 | 0.120 |
Why?
|
Asymptomatic Diseases | 1 | 2018 | 588 | 0.120 |
Why?
|
Hearing Loss | 1 | 2022 | 783 | 0.120 |
Why?
|
Cell Line, Tumor | 16 | 2021 | 16981 | 0.120 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2019 | 423 | 0.120 |
Why?
|
Soft Tissue Neoplasms | 2 | 2014 | 1159 | 0.120 |
Why?
|
Time Factors | 23 | 2021 | 39967 | 0.120 |
Why?
|
Pyrimidines | 2 | 2018 | 3028 | 0.120 |
Why?
|
T-Lymphocytes | 6 | 2018 | 10194 | 0.120 |
Why?
|
Teratoma | 2 | 2017 | 404 | 0.120 |
Why?
|
Urate Oxidase | 1 | 2014 | 31 | 0.110 |
Why?
|
Guanine | 2 | 2012 | 279 | 0.110 |
Why?
|
Glutamates | 2 | 2012 | 389 | 0.110 |
Why?
|
Myeloablative Agonists | 1 | 2014 | 209 | 0.110 |
Why?
|
Fibromatosis, Abdominal | 1 | 2012 | 21 | 0.110 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2020 | 926 | 0.110 |
Why?
|
Myxosarcoma | 1 | 2012 | 11 | 0.110 |
Why?
|
Multivariate Analysis | 5 | 2020 | 12059 | 0.100 |
Why?
|
Child | 23 | 2024 | 80153 | 0.100 |
Why?
|
Anticonvulsants | 1 | 2022 | 1906 | 0.100 |
Why?
|
Retinal Neoplasms | 1 | 2014 | 146 | 0.100 |
Why?
|
Gene Expression | 5 | 2014 | 7581 | 0.100 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2015 | 718 | 0.100 |
Why?
|
Registries | 4 | 2019 | 8224 | 0.100 |
Why?
|
Genotype | 11 | 2017 | 12990 | 0.100 |
Why?
|
Sulfones | 1 | 2015 | 448 | 0.100 |
Why?
|
Carcinoma, Large Cell | 1 | 2012 | 113 | 0.100 |
Why?
|
Hepatocyte Nuclear Factor 3-beta | 1 | 2012 | 64 | 0.100 |
Why?
|
Lymphoma | 3 | 2018 | 1901 | 0.100 |
Why?
|
Asbestos | 1 | 2013 | 251 | 0.100 |
Why?
|
Neoplasm Proteins | 5 | 2009 | 3617 | 0.100 |
Why?
|
Tissue Fixation | 2 | 2016 | 241 | 0.100 |
Why?
|
Interferon-gamma | 2 | 2011 | 3162 | 0.100 |
Why?
|
Lymphocyte Transfusion | 1 | 2012 | 232 | 0.100 |
Why?
|
Leucovorin | 6 | 2021 | 643 | 0.090 |
Why?
|
Carcinogens | 1 | 2013 | 452 | 0.090 |
Why?
|
Chimera | 1 | 2012 | 453 | 0.090 |
Why?
|
Esophagectomy | 1 | 2015 | 468 | 0.090 |
Why?
|
Quality of Life | 7 | 2023 | 13367 | 0.090 |
Why?
|
Esophageal Neoplasms | 2 | 2015 | 1654 | 0.090 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 6 | 2018 | 1745 | 0.090 |
Why?
|
Hematologic Neoplasms | 3 | 2014 | 1896 | 0.090 |
Why?
|
Treatment Failure | 7 | 2017 | 2645 | 0.090 |
Why?
|
Chordoma | 1 | 2014 | 347 | 0.090 |
Why?
|
Extremities | 2 | 2014 | 867 | 0.090 |
Why?
|
Granulocyte Colony-Stimulating Factor | 3 | 2011 | 629 | 0.090 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2019 | 4026 | 0.090 |
Why?
|
Fibrosarcoma | 1 | 2012 | 309 | 0.090 |
Why?
|
Chimerism | 1 | 2011 | 155 | 0.090 |
Why?
|
Neoplasms | 7 | 2021 | 22170 | 0.090 |
Why?
|
Translocation, Genetic | 1 | 2016 | 1393 | 0.090 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2014 | 646 | 0.090 |
Why?
|
Hematopoietic Stem Cell Mobilization | 2 | 2011 | 225 | 0.090 |
Why?
|
Disease Progression | 10 | 2021 | 13506 | 0.090 |
Why?
|
Tumor Suppressor Proteins | 1 | 2020 | 2803 | 0.090 |
Why?
|
Data Collection | 1 | 2019 | 3322 | 0.090 |
Why?
|
Neutropenia | 3 | 2011 | 885 | 0.090 |
Why?
|
Genes, erbB-1 | 1 | 2010 | 162 | 0.090 |
Why?
|
Histocompatibility Testing | 2 | 2009 | 712 | 0.090 |
Why?
|
Swine Diseases | 1 | 2009 | 61 | 0.090 |
Why?
|
Thoracic Surgical Procedures | 1 | 2013 | 349 | 0.080 |
Why?
|
Immunohistochemistry | 9 | 2020 | 11076 | 0.080 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2013 | 549 | 0.080 |
Why?
|
Biopsy, Fine-Needle | 2 | 2014 | 1118 | 0.080 |
Why?
|
Spinal Cord | 2 | 2015 | 1818 | 0.080 |
Why?
|
Umbilical Cord | 1 | 2010 | 177 | 0.080 |
Why?
|
Lymph Nodes | 2 | 2019 | 3466 | 0.080 |
Why?
|
B-Lymphocytes | 4 | 2011 | 4758 | 0.080 |
Why?
|
Tumor Burden | 4 | 2018 | 1893 | 0.080 |
Why?
|
Body Height | 1 | 2015 | 1570 | 0.080 |
Why?
|
Receptors, Growth Factor | 1 | 2010 | 326 | 0.080 |
Why?
|
Immunotherapy | 3 | 2021 | 4652 | 0.080 |
Why?
|
Breast | 1 | 2018 | 1967 | 0.080 |
Why?
|
SOXB1 Transcription Factors | 1 | 2010 | 286 | 0.080 |
Why?
|
Feasibility Studies | 6 | 2019 | 5247 | 0.080 |
Why?
|
Lung Diseases | 3 | 2007 | 1909 | 0.080 |
Why?
|
Cell Transplantation | 1 | 2010 | 472 | 0.080 |
Why?
|
Hodgkin Disease | 2 | 2013 | 1378 | 0.080 |
Why?
|
Meningioma | 1 | 2017 | 1218 | 0.080 |
Why?
|
Neoplasms, Second Primary | 2 | 2013 | 1052 | 0.080 |
Why?
|
Risk Factors | 14 | 2021 | 74206 | 0.080 |
Why?
|
Gene Expression Regulation, Neoplastic | 8 | 2020 | 8547 | 0.080 |
Why?
|
Estradiol | 1 | 2015 | 1937 | 0.080 |
Why?
|
beta Catenin | 1 | 2013 | 1040 | 0.080 |
Why?
|
Rhabdomyosarcoma | 1 | 2011 | 358 | 0.070 |
Why?
|
Lung | 3 | 2018 | 10000 | 0.070 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 4 | 2014 | 4575 | 0.070 |
Why?
|
Transplantation Chimera | 2 | 2007 | 594 | 0.070 |
Why?
|
Survivors | 3 | 2018 | 2371 | 0.070 |
Why?
|
Genes, ras | 4 | 2014 | 654 | 0.070 |
Why?
|
Alleles | 3 | 2021 | 6863 | 0.070 |
Why?
|
Infant | 11 | 2021 | 36192 | 0.070 |
Why?
|
Spine | 1 | 2014 | 1118 | 0.070 |
Why?
|
Respiration | 1 | 2013 | 1657 | 0.070 |
Why?
|
Drug Administration Schedule | 7 | 2015 | 4853 | 0.070 |
Why?
|
Pulmonary Surgical Procedures | 1 | 2007 | 34 | 0.070 |
Why?
|
Frozen Sections | 1 | 2007 | 153 | 0.070 |
Why?
|
Xeroderma Pigmentosum Group D Protein | 1 | 2007 | 106 | 0.070 |
Why?
|
Proportional Hazards Models | 8 | 2019 | 12463 | 0.070 |
Why?
|
Apoptosis | 6 | 2019 | 9486 | 0.070 |
Why?
|
Xenograft Model Antitumor Assays | 5 | 2019 | 3602 | 0.070 |
Why?
|
Polymorphism, Genetic | 2 | 2007 | 4243 | 0.070 |
Why?
|
DNA, Neoplasm | 2 | 2009 | 1745 | 0.070 |
Why?
|
Craniopharyngioma | 1 | 2009 | 277 | 0.070 |
Why?
|
Ovarian Neoplasms | 3 | 1998 | 4876 | 0.070 |
Why?
|
Vincristine | 7 | 2020 | 1036 | 0.060 |
Why?
|
Organs at Risk | 2 | 2022 | 359 | 0.060 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2009 | 664 | 0.060 |
Why?
|
Amino Acid Substitution | 2 | 2021 | 1738 | 0.060 |
Why?
|
Total Quality Management | 1 | 2007 | 265 | 0.060 |
Why?
|
Models, Statistical | 1 | 2020 | 5079 | 0.060 |
Why?
|
Fundoplication | 1 | 2006 | 144 | 0.060 |
Why?
|
Jehovah's Witnesses | 1 | 2004 | 13 | 0.060 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2009 | 686 | 0.060 |
Why?
|
Body Weight | 1 | 2015 | 4618 | 0.060 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2012 | 2865 | 0.060 |
Why?
|
Testosterone | 1 | 2015 | 2472 | 0.060 |
Why?
|
Down-Regulation | 1 | 2012 | 2919 | 0.060 |
Why?
|
Pleura | 1 | 2006 | 245 | 0.060 |
Why?
|
Immunity, Cellular | 1 | 2010 | 1560 | 0.060 |
Why?
|
Lymphoma, B-Cell | 1 | 1991 | 940 | 0.060 |
Why?
|
Whole-Body Irradiation | 3 | 2009 | 433 | 0.060 |
Why?
|
Smoking | 2 | 2012 | 9053 | 0.060 |
Why?
|
Liver | 1 | 2020 | 7529 | 0.060 |
Why?
|
Morpholines | 1 | 2007 | 581 | 0.060 |
Why?
|
Fever | 1 | 2011 | 1618 | 0.060 |
Why?
|
Genes, Tumor Suppressor | 1 | 2008 | 1062 | 0.060 |
Why?
|
Algorithms | 2 | 2021 | 14031 | 0.060 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 3 | 2022 | 1661 | 0.060 |
Why?
|
Cysts | 1 | 2009 | 681 | 0.060 |
Why?
|
Leukemia | 1 | 2011 | 1522 | 0.050 |
Why?
|
Radiography | 5 | 2015 | 6965 | 0.050 |
Why?
|
Boronic Acids | 1 | 2007 | 915 | 0.050 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 1 | 2004 | 263 | 0.050 |
Why?
|
Genetic Linkage | 1 | 2008 | 2341 | 0.050 |
Why?
|
Graft Survival | 3 | 2009 | 3819 | 0.050 |
Why?
|
Solitary Pulmonary Nodule | 1 | 2006 | 278 | 0.050 |
Why?
|
Cyclophosphamide | 10 | 2008 | 2218 | 0.050 |
Why?
|
Paraffin Embedding | 2 | 2016 | 302 | 0.050 |
Why?
|
Skin Neoplasms | 2 | 2012 | 5821 | 0.050 |
Why?
|
Transplantation, Homologous | 4 | 2014 | 4806 | 0.050 |
Why?
|
Antibodies, Monoclonal | 4 | 2009 | 9177 | 0.050 |
Why?
|
Immune Tolerance | 1 | 2011 | 2303 | 0.050 |
Why?
|
Oligonucleotide Array Sequence Analysis | 4 | 2014 | 3778 | 0.050 |
Why?
|
Histocompatibility Antigens Class II | 2 | 2021 | 1435 | 0.050 |
Why?
|
United States Department of Veterans Affairs | 1 | 2007 | 928 | 0.050 |
Why?
|
Fatigue | 2 | 2023 | 1552 | 0.050 |
Why?
|
Colorectal Neoplasms | 1 | 2021 | 6935 | 0.050 |
Why?
|
Cohort Studies | 8 | 2022 | 41487 | 0.050 |
Why?
|
Hematopoietic Stem Cells | 2 | 2011 | 3396 | 0.050 |
Why?
|
Lymphatic Metastasis | 3 | 2018 | 2915 | 0.050 |
Why?
|
Cognition Disorders | 1 | 2016 | 3979 | 0.050 |
Why?
|
Transplantation, Autologous | 5 | 2007 | 2115 | 0.050 |
Why?
|
Cell Proliferation | 4 | 2010 | 10445 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 5 | 2012 | 17904 | 0.050 |
Why?
|
Autoantibodies | 1 | 2010 | 2116 | 0.050 |
Why?
|
Signal Transduction | 4 | 2016 | 23445 | 0.050 |
Why?
|
RNA, Neoplasm | 3 | 2010 | 750 | 0.050 |
Why?
|
Recurrence | 6 | 2019 | 8465 | 0.050 |
Why?
|
Pyrazines | 1 | 2007 | 1201 | 0.050 |
Why?
|
Age Factors | 7 | 2021 | 18395 | 0.050 |
Why?
|
Risk Assessment | 8 | 2017 | 23995 | 0.050 |
Why?
|
Confidence Intervals | 2 | 2017 | 2927 | 0.050 |
Why?
|
Waiting Lists | 1 | 2006 | 765 | 0.050 |
Why?
|
Leukemia, Promyelocytic, Acute | 1 | 2002 | 251 | 0.050 |
Why?
|
Nausea | 1 | 2024 | 679 | 0.050 |
Why?
|
Hepatocyte Growth Factor | 2 | 2014 | 270 | 0.050 |
Why?
|
Vomiting | 1 | 2024 | 651 | 0.040 |
Why?
|
Melphalan | 2 | 2007 | 420 | 0.040 |
Why?
|
Biopsy | 3 | 2021 | 6766 | 0.040 |
Why?
|
Parathyroid Hormone | 1 | 2007 | 1803 | 0.040 |
Why?
|
Antigens, Differentiation, B-Lymphocyte | 1 | 2021 | 317 | 0.040 |
Why?
|
Ambulatory Care | 1 | 2011 | 2775 | 0.040 |
Why?
|
Graft Rejection | 2 | 2011 | 4445 | 0.040 |
Why?
|
Least-Squares Analysis | 1 | 2001 | 369 | 0.040 |
Why?
|
Australia | 2 | 2015 | 1250 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 6 | 2018 | 20570 | 0.040 |
Why?
|
Radiation Tolerance | 2 | 2015 | 479 | 0.040 |
Why?
|
Remission Induction | 7 | 2014 | 2396 | 0.040 |
Why?
|
Blood Cell Count | 1 | 2020 | 397 | 0.040 |
Why?
|
Doxorubicin | 8 | 2012 | 2224 | 0.040 |
Why?
|
Microsatellite Repeats | 1 | 2021 | 784 | 0.040 |
Why?
|
Animals | 17 | 2019 | 168459 | 0.040 |
Why?
|
Mice | 13 | 2019 | 81525 | 0.040 |
Why?
|
Bone Neoplasms | 1 | 2011 | 2529 | 0.040 |
Why?
|
Genomic Instability | 1 | 2023 | 709 | 0.040 |
Why?
|
Prostatic Neoplasms | 4 | 2013 | 11118 | 0.040 |
Why?
|
Colostomy | 1 | 2019 | 105 | 0.040 |
Why?
|
Lymphocyte Count | 1 | 2021 | 778 | 0.040 |
Why?
|
Pancreaticoduodenectomy | 2 | 2014 | 509 | 0.040 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2023 | 612 | 0.040 |
Why?
|
Canada | 1 | 2024 | 2122 | 0.040 |
Why?
|
Gastroesophageal Reflux | 1 | 2006 | 819 | 0.040 |
Why?
|
Mitomycin | 1 | 2019 | 263 | 0.040 |
Why?
|
Interleukin-7 Receptor alpha Subunit | 1 | 2018 | 50 | 0.040 |
Why?
|
Epigenesis, Genetic | 1 | 2012 | 3802 | 0.040 |
Why?
|
Predictive Value of Tests | 6 | 2013 | 15266 | 0.040 |
Why?
|
Patient Discharge | 1 | 2011 | 3443 | 0.040 |
Why?
|
Cell Nucleus | 2 | 2020 | 2909 | 0.040 |
Why?
|
Germ-Line Mutation | 2 | 2021 | 1858 | 0.040 |
Why?
|
Models, Genetic | 1 | 2008 | 3442 | 0.040 |
Why?
|
Tumor Cells, Cultured | 2 | 2020 | 6132 | 0.040 |
Why?
|
Busulfan | 2 | 2008 | 258 | 0.040 |
Why?
|
Incidence | 4 | 2019 | 21353 | 0.040 |
Why?
|
Hearing | 1 | 2022 | 501 | 0.040 |
Why?
|
Sex Factors | 4 | 2016 | 10552 | 0.040 |
Why?
|
Swine, Miniature | 2 | 2010 | 961 | 0.040 |
Why?
|
Mice, Inbred BALB C | 3 | 2012 | 6216 | 0.040 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2024 | 10209 | 0.040 |
Why?
|
Transplantation Immunology | 2 | 2010 | 532 | 0.040 |
Why?
|
Receptors, Androgen | 1 | 2024 | 1079 | 0.040 |
Why?
|
Respiratory System | 1 | 2001 | 563 | 0.040 |
Why?
|
Ozone | 1 | 2001 | 483 | 0.040 |
Why?
|
Anilides | 1 | 2020 | 411 | 0.040 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2020 | 3639 | 0.040 |
Why?
|
Isoantibodies | 2 | 2011 | 674 | 0.040 |
Why?
|
Mutation, Missense | 1 | 2006 | 2571 | 0.040 |
Why?
|
X-Linked Inhibitor of Apoptosis Protein | 2 | 2007 | 61 | 0.030 |
Why?
|
Lymphocyte Subsets | 1 | 2018 | 310 | 0.030 |
Why?
|
Molecular Diagnostic Techniques | 2 | 2013 | 611 | 0.030 |
Why?
|
Pilot Projects | 2 | 2021 | 8631 | 0.030 |
Why?
|
Antilymphocyte Serum | 2 | 2010 | 487 | 0.030 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2018 | 306 | 0.030 |
Why?
|
Phthalazines | 1 | 2019 | 383 | 0.030 |
Why?
|
Patient Selection | 3 | 2015 | 4244 | 0.030 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2020 | 621 | 0.030 |
Why?
|
Leukocyte Transfusion | 2 | 2009 | 56 | 0.030 |
Why?
|
Lymphocyte Depletion | 2 | 2012 | 602 | 0.030 |
Why?
|
Sensitivity and Specificity | 4 | 2014 | 14666 | 0.030 |
Why?
|
Anal Canal | 1 | 2019 | 373 | 0.030 |
Why?
|
Aging | 1 | 2015 | 8708 | 0.030 |
Why?
|
Diethylstilbestrol | 1 | 1996 | 87 | 0.030 |
Why?
|
Gene Dosage | 2 | 2012 | 1217 | 0.030 |
Why?
|
Colonic Neoplasms | 1 | 2008 | 2538 | 0.030 |
Why?
|
Lung Transplantation | 1 | 2006 | 1310 | 0.030 |
Why?
|
Neoplasm Invasiveness | 2 | 2016 | 3595 | 0.030 |
Why?
|
Hormones | 1 | 2020 | 869 | 0.030 |
Why?
|
Intention to Treat Analysis | 1 | 2017 | 413 | 0.030 |
Why?
|
Flutamide | 1 | 1996 | 95 | 0.030 |
Why?
|
Thoracic Wall | 1 | 2018 | 202 | 0.030 |
Why?
|
Serotonin | 1 | 2001 | 1041 | 0.030 |
Why?
|
Benzimidazoles | 1 | 2021 | 858 | 0.030 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2020 | 736 | 0.030 |
Why?
|
Neoplasm, Residual | 2 | 2012 | 1008 | 0.030 |
Why?
|
Faculty, Medical | 1 | 2024 | 1203 | 0.030 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2007 | 4352 | 0.030 |
Why?
|
Drug Therapy, Combination | 2 | 2019 | 6310 | 0.030 |
Why?
|
Structure-Activity Relationship | 1 | 2021 | 3076 | 0.030 |
Why?
|
Surgical Procedures, Operative | 1 | 2007 | 1922 | 0.030 |
Why?
|
Case-Control Studies | 5 | 2015 | 22176 | 0.030 |
Why?
|
Esophagus | 1 | 2021 | 1033 | 0.030 |
Why?
|
Alprazolam | 1 | 1995 | 102 | 0.030 |
Why?
|
Formaldehyde | 1 | 2016 | 358 | 0.030 |
Why?
|
Enzyme Activation | 2 | 2012 | 3597 | 0.030 |
Why?
|
Anovulation | 1 | 1995 | 54 | 0.030 |
Why?
|
Neoplasm Metastasis | 4 | 2018 | 4915 | 0.030 |
Why?
|
Astrocytoma | 1 | 2019 | 775 | 0.030 |
Why?
|
Kidney Transplantation | 1 | 2010 | 4234 | 0.030 |
Why?
|
Odds Ratio | 4 | 2009 | 9646 | 0.030 |
Why?
|
Bleomycin | 6 | 1991 | 494 | 0.030 |
Why?
|
BRCA1 Protein | 1 | 2021 | 1155 | 0.030 |
Why?
|
Radiometry | 1 | 2020 | 813 | 0.030 |
Why?
|
Linear Energy Transfer | 1 | 2015 | 152 | 0.030 |
Why?
|
Nuclear Proteins | 1 | 2009 | 5796 | 0.030 |
Why?
|
Family Characteristics | 1 | 2019 | 1004 | 0.030 |
Why?
|
Postoperative Complications | 3 | 2012 | 15631 | 0.030 |
Why?
|
Bone Marrow Cells | 2 | 2012 | 2416 | 0.030 |
Why?
|
Trimetrexate | 1 | 1994 | 15 | 0.030 |
Why?
|
Clinical Trials as Topic | 2 | 2009 | 8002 | 0.030 |
Why?
|
Liposarcoma, Myxoid | 1 | 2014 | 60 | 0.030 |
Why?
|
Base Sequence | 3 | 2012 | 12441 | 0.030 |
Why?
|
Histiocytoma, Malignant Fibrous | 1 | 2014 | 55 | 0.030 |
Why?
|
Receptors, CXCR | 1 | 2014 | 52 | 0.030 |
Why?
|
CA-19-9 Antigen | 1 | 2014 | 106 | 0.030 |
Why?
|
Laparoscopy | 1 | 2006 | 2035 | 0.030 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2001 | 954 | 0.030 |
Why?
|
Adaptor Proteins, Signal Transducing | 3 | 2009 | 2898 | 0.030 |
Why?
|
International Cooperation | 1 | 2019 | 1422 | 0.030 |
Why?
|
Practice Guidelines as Topic | 1 | 2010 | 7390 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2021 | 1089 | 0.030 |
Why?
|
Mesna | 1 | 2012 | 62 | 0.030 |
Why?
|
Sarcoma, Synovial | 1 | 2014 | 153 | 0.030 |
Why?
|
Carcinoembryonic Antigen | 1 | 2014 | 337 | 0.030 |
Why?
|
Analysis of Variance | 2 | 2013 | 6228 | 0.030 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2018 | 4369 | 0.030 |
Why?
|
Anti-Bacterial Agents | 1 | 2011 | 7407 | 0.030 |
Why?
|
Thymidylate Synthase | 1 | 2012 | 74 | 0.030 |
Why?
|
Mastectomy, Segmental | 1 | 2018 | 955 | 0.030 |
Why?
|
Reproducibility of Results | 3 | 2021 | 20098 | 0.030 |
Why?
|
Exanthema | 2 | 2007 | 503 | 0.030 |
Why?
|
Immunosuppressive Agents | 3 | 2010 | 4174 | 0.030 |
Why?
|
Luteinizing Hormone | 1 | 1995 | 820 | 0.030 |
Why?
|
Immunologic Factors | 1 | 2021 | 1589 | 0.030 |
Why?
|
Radiation Pneumonitis | 1 | 2013 | 102 | 0.030 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 2013 | 296 | 0.030 |
Why?
|
Ifosfamide | 1 | 2012 | 232 | 0.030 |
Why?
|
Sacrum | 1 | 2014 | 276 | 0.020 |
Why?
|
Adenocarcinoma, Papillary | 1 | 2012 | 84 | 0.020 |
Why?
|
Phosphorylation | 3 | 2009 | 8320 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2018 | 4580 | 0.020 |
Why?
|
Supratentorial Neoplasms | 1 | 2013 | 159 | 0.020 |
Why?
|
Carcinoma, Signet Ring Cell | 1 | 2012 | 82 | 0.020 |
Why?
|
Chromatography, Liquid | 1 | 2015 | 983 | 0.020 |
Why?
|
Microtubule-Associated Proteins | 2 | 2007 | 1076 | 0.020 |
Why?
|
Neuropsychological Tests | 2 | 2016 | 7045 | 0.020 |
Why?
|
Chondrosarcoma | 1 | 2014 | 296 | 0.020 |
Why?
|
Depressive Disorder, Major | 1 | 2009 | 4761 | 0.020 |
Why?
|
Endometrial Neoplasms | 1 | 2001 | 1366 | 0.020 |
Why?
|
Codon | 1 | 2013 | 601 | 0.020 |
Why?
|
Databases, Factual | 3 | 2015 | 7967 | 0.020 |
Why?
|
Receptors, Interferon | 1 | 2011 | 116 | 0.020 |
Why?
|
United States | 6 | 2024 | 72334 | 0.020 |
Why?
|
Blood Loss, Surgical | 1 | 2015 | 637 | 0.020 |
Why?
|
Recombinant Proteins | 2 | 2014 | 6534 | 0.020 |
Why?
|
Iohexol | 1 | 2012 | 204 | 0.020 |
Why?
|
Life Tables | 1 | 1991 | 364 | 0.020 |
Why?
|
Rhabdomyosarcoma, Alveolar | 1 | 2011 | 42 | 0.020 |
Why?
|
Medical Oncology | 1 | 2023 | 2321 | 0.020 |
Why?
|
Models, Molecular | 1 | 2021 | 5439 | 0.020 |
Why?
|
Intermediate Filament Proteins | 1 | 2011 | 262 | 0.020 |
Why?
|
Regression Analysis | 2 | 2012 | 6343 | 0.020 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2009 | 2057 | 0.020 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 2 | 1991 | 1405 | 0.020 |
Why?
|
Growth Disorders | 1 | 2015 | 655 | 0.020 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2014 | 592 | 0.020 |
Why?
|
Mice, Inbred C57BL | 5 | 2012 | 22169 | 0.020 |
Why?
|
Diarrhea | 2 | 2007 | 1318 | 0.020 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 1092 | 0.020 |
Why?
|
Up-Regulation | 2 | 2011 | 4124 | 0.020 |
Why?
|
Inbreeding | 1 | 2009 | 48 | 0.020 |
Why?
|
Rhabdomyosarcoma, Embryonal | 1 | 2011 | 100 | 0.020 |
Why?
|
Reoperation | 2 | 2013 | 4303 | 0.020 |
Why?
|
Pulmonary Alveoli | 1 | 2013 | 652 | 0.020 |
Why?
|
Monte Carlo Method | 1 | 2015 | 1258 | 0.020 |
Why?
|
Swine | 2 | 2010 | 5915 | 0.020 |
Why?
|
Necrosis | 1 | 2014 | 1611 | 0.020 |
Why?
|
Hippocampus | 1 | 2022 | 3766 | 0.020 |
Why?
|
Western World | 1 | 2009 | 27 | 0.020 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2011 | 326 | 0.020 |
Why?
|
Mitotic Index | 1 | 2010 | 162 | 0.020 |
Why?
|
Transfection | 2 | 2009 | 5774 | 0.020 |
Why?
|
Radiation Injuries, Experimental | 1 | 1990 | 88 | 0.020 |
Why?
|
Blotting, Western | 2 | 2009 | 5035 | 0.020 |
Why?
|
Photography | 1 | 2013 | 532 | 0.020 |
Why?
|
Tissue Donors | 2 | 2010 | 2331 | 0.020 |
Why?
|
Dacarbazine | 1 | 2012 | 559 | 0.020 |
Why?
|
Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2009 | 103 | 0.020 |
Why?
|
Transcription Factors | 1 | 2009 | 12128 | 0.020 |
Why?
|
Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2009 | 89 | 0.020 |
Why?
|
Chemokine CXCL12 | 1 | 2011 | 454 | 0.020 |
Why?
|
Thoracic Vertebrae | 1 | 2014 | 597 | 0.020 |
Why?
|
Prednisolone | 1 | 2010 | 326 | 0.020 |
Why?
|
DNA-Binding Proteins | 1 | 2007 | 9606 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2009 | 2455 | 0.020 |
Why?
|
Antigens, CD34 | 1 | 2011 | 658 | 0.020 |
Why?
|
Genomics | 1 | 2005 | 5821 | 0.020 |
Why?
|
Cervical Vertebrae | 1 | 2015 | 980 | 0.020 |
Why?
|
Radiation Chimera | 1 | 2009 | 216 | 0.020 |
Why?
|
Injections, Subcutaneous | 1 | 2010 | 681 | 0.020 |
Why?
|
Methotrexate | 6 | 1991 | 1719 | 0.020 |
Why?
|
Flow Cytometry | 2 | 2011 | 5869 | 0.020 |
Why?
|
Medical History Taking | 1 | 2012 | 774 | 0.020 |
Why?
|
Anemia, Hemolytic | 1 | 1990 | 162 | 0.020 |
Why?
|
Radiation Dosage | 1 | 2017 | 1958 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2018 | 2200 | 0.020 |
Why?
|
Piperazines | 1 | 2019 | 2523 | 0.020 |
Why?
|
Cytogenetic Analysis | 1 | 2009 | 270 | 0.020 |
Why?
|
Probability | 2 | 1991 | 2477 | 0.020 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2009 | 411 | 0.020 |
Why?
|
Online Systems | 1 | 2009 | 182 | 0.020 |
Why?
|
Disease Management | 1 | 2019 | 2508 | 0.020 |
Why?
|
Leukocytosis | 1 | 2009 | 251 | 0.020 |
Why?
|
Consensus | 1 | 2018 | 3123 | 0.020 |
Why?
|
Cell Survival | 2 | 2009 | 5791 | 0.020 |
Why?
|
Abdominal Neoplasms | 1 | 1990 | 287 | 0.020 |
Why?
|
Promoter Regions, Genetic | 2 | 2012 | 5789 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2015 | 2192 | 0.020 |
Why?
|
Lymphopoiesis | 1 | 2009 | 133 | 0.020 |
Why?
|
Dexamethasone | 6 | 1991 | 1948 | 0.020 |
Why?
|
Reference Values | 1 | 2015 | 4920 | 0.020 |
Why?
|
Diaphragm | 1 | 1990 | 351 | 0.020 |
Why?
|
Cause of Death | 1 | 2019 | 3683 | 0.020 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2012 | 732 | 0.020 |
Why?
|
MAP Kinase Kinase Kinases | 1 | 2009 | 255 | 0.020 |
Why?
|
Quinazolinones | 1 | 2010 | 221 | 0.020 |
Why?
|
Cerebellum | 1 | 2015 | 1501 | 0.020 |
Why?
|
Therapeutic Irrigation | 1 | 2009 | 292 | 0.020 |
Why?
|
Length of Stay | 2 | 2013 | 6425 | 0.020 |
Why?
|
Cytarabine | 1 | 2010 | 697 | 0.020 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 1996 | 1520 | 0.020 |
Why?
|
Self Report | 1 | 2019 | 3724 | 0.020 |
Why?
|
Genes, Intracisternal A-Particle | 1 | 2007 | 4 | 0.020 |
Why?
|
Cyclosporine | 1 | 2010 | 778 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2009 | 10766 | 0.020 |
Why?
|
Uric Acid | 1 | 2014 | 807 | 0.020 |
Why?
|
Macrocyclic Compounds | 1 | 2007 | 68 | 0.020 |
Why?
|
Receptors, Complement 3b | 1 | 2007 | 135 | 0.020 |
Why?
|
Prescriptions | 1 | 2010 | 386 | 0.020 |
Why?
|
Androgen Antagonists | 1 | 1996 | 1410 | 0.020 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2012 | 899 | 0.020 |
Why?
|
NIH 3T3 Cells | 1 | 2009 | 670 | 0.020 |
Why?
|
Stress, Physiological | 1 | 1995 | 1403 | 0.020 |
Why?
|
Erythroblasts | 1 | 2007 | 142 | 0.020 |
Why?
|
Pyruvate Kinase | 1 | 2009 | 189 | 0.020 |
Why?
|
Upper Extremity | 1 | 2012 | 657 | 0.020 |
Why?
|
Visual Perception | 1 | 2016 | 1387 | 0.020 |
Why?
|
Computational Biology | 1 | 2019 | 3518 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2013 | 3416 | 0.020 |
Why?
|
Filgrastim | 1 | 2007 | 132 | 0.020 |
Why?
|
Methods | 1 | 1987 | 1067 | 0.020 |
Why?
|
Hydrocortisone | 1 | 1995 | 1819 | 0.020 |
Why?
|
Air Pollutants | 1 | 2001 | 2896 | 0.020 |
Why?
|
Bone Marrow | 3 | 2011 | 2911 | 0.020 |
Why?
|
Penetrance | 1 | 2008 | 383 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2009 | 1705 | 0.020 |
Why?
|
RNA, Messenger | 3 | 2007 | 12795 | 0.020 |
Why?
|
Multicenter Studies as Topic | 1 | 2011 | 1702 | 0.020 |
Why?
|
In Situ Hybridization | 1 | 2010 | 1900 | 0.020 |
Why?
|
Central Nervous System | 1 | 2013 | 1336 | 0.020 |
Why?
|
Learning | 1 | 2016 | 1740 | 0.020 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2008 | 882 | 0.020 |
Why?
|
Drug Resistance, Multiple | 1 | 2007 | 255 | 0.020 |
Why?
|
Paclitaxel | 1 | 1993 | 1732 | 0.020 |
Why?
|
Skin Transplantation | 1 | 2011 | 1083 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2013 | 2707 | 0.020 |
Why?
|
Cell Separation | 1 | 2011 | 1720 | 0.020 |
Why?
|
Autoantigens | 1 | 2010 | 891 | 0.020 |
Why?
|
Adjuvants, Immunologic | 1 | 2011 | 1036 | 0.020 |
Why?
|
Antibody Formation | 1 | 2010 | 1395 | 0.020 |
Why?
|
Vidarabine | 1 | 2007 | 336 | 0.020 |
Why?
|
Mycophenolic Acid | 1 | 2007 | 348 | 0.020 |
Why?
|
Receptor, erbB-3 | 1 | 2006 | 143 | 0.020 |
Why?
|
DNA Primers | 1 | 2009 | 2819 | 0.020 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2015 | 3769 | 0.020 |
Why?
|
Attention | 1 | 2016 | 2396 | 0.020 |
Why?
|
Sample Size | 1 | 2008 | 841 | 0.020 |
Why?
|
Evaluation Studies as Topic | 1 | 1987 | 1624 | 0.020 |
Why?
|
Antigens, Surface | 1 | 2009 | 1606 | 0.010 |
Why?
|
Mice, Knockout | 2 | 2011 | 14414 | 0.010 |
Why?
|
Cell Count | 1 | 2009 | 1835 | 0.010 |
Why?
|
Diagnosis, Differential | 2 | 2013 | 12974 | 0.010 |
Why?
|
Visual Acuity | 1 | 2014 | 2672 | 0.010 |
Why?
|
Rats | 1 | 2001 | 23742 | 0.010 |
Why?
|
Altretamine | 2 | 1996 | 11 | 0.010 |
Why?
|
Mastectomy | 1 | 2013 | 1822 | 0.010 |
Why?
|
Interleukin-11 | 1 | 2004 | 58 | 0.010 |
Why?
|
Immunologic Memory | 1 | 2011 | 1359 | 0.010 |
Why?
|
Lumbar Vertebrae | 1 | 2014 | 1879 | 0.010 |
Why?
|
Genetics, Population | 1 | 2009 | 937 | 0.010 |
Why?
|
Carcinoma | 1 | 1996 | 2330 | 0.010 |
Why?
|
Lower Extremity | 1 | 2012 | 1202 | 0.010 |
Why?
|
Anemia | 2 | 2009 | 1509 | 0.010 |
Why?
|
Bronchiolitis Obliterans | 1 | 2006 | 213 | 0.010 |
Why?
|
Pathology, Molecular | 1 | 2007 | 328 | 0.010 |
Why?
|
Carcinoma, Papillary | 1 | 2009 | 785 | 0.010 |
Why?
|
Epithelium | 1 | 2009 | 1603 | 0.010 |
Why?
|
Introns | 1 | 2007 | 981 | 0.010 |
Why?
|
Cell Death | 1 | 2009 | 1678 | 0.010 |
Why?
|
Cell Communication | 1 | 2011 | 1657 | 0.010 |
Why?
|
Quinolines | 1 | 2009 | 764 | 0.010 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 615 | 0.010 |
Why?
|
Protozoan Infections | 1 | 2003 | 38 | 0.010 |
Why?
|
Rabbits | 1 | 2010 | 4772 | 0.010 |
Why?
|
Maximum Tolerated Dose | 1 | 2006 | 883 | 0.010 |
Why?
|
Imidazoles | 1 | 2009 | 1180 | 0.010 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2009 | 1349 | 0.010 |
Why?
|
Leukopenia | 2 | 1994 | 213 | 0.010 |
Why?
|
Acute Disease | 1 | 2014 | 7237 | 0.010 |
Why?
|
Lymphocyte Activation | 1 | 2014 | 5486 | 0.010 |
Why?
|
Stem Cell Transplantation | 1 | 2011 | 1600 | 0.010 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 3810 | 0.010 |
Why?
|
Mammaplasty | 1 | 2013 | 1239 | 0.010 |
Why?
|
Osteosarcoma | 1 | 2008 | 897 | 0.010 |
Why?
|
Employment | 1 | 2009 | 1118 | 0.010 |
Why?
|
Hot Temperature | 1 | 2009 | 1440 | 0.010 |
Why?
|
Social Behavior | 1 | 2009 | 1135 | 0.010 |
Why?
|
Administration, Oral | 2 | 2004 | 4021 | 0.010 |
Why?
|
Mice, Nude | 1 | 2009 | 3615 | 0.010 |
Why?
|
Protein Kinases | 1 | 2009 | 1608 | 0.010 |
Why?
|
Sirolimus | 1 | 2009 | 1533 | 0.010 |
Why?
|
Homozygote | 1 | 2007 | 1776 | 0.010 |
Why?
|
Fetal Blood | 1 | 2009 | 1347 | 0.010 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2007 | 1334 | 0.010 |
Why?
|
Sequence Deletion | 1 | 2006 | 1494 | 0.010 |
Why?
|
Platelet Count | 1 | 2004 | 781 | 0.010 |
Why?
|
Logistic Models | 2 | 2012 | 13255 | 0.010 |
Why?
|
Megestrol | 1 | 2001 | 9 | 0.010 |
Why?
|
Biopsy, Needle | 1 | 2006 | 1626 | 0.010 |
Why?
|
Aspergillosis | 1 | 2003 | 242 | 0.010 |
Why?
|
Epidermal Growth Factor | 1 | 2004 | 701 | 0.010 |
Why?
|
Gram-Negative Bacterial Infections | 1 | 2003 | 238 | 0.010 |
Why?
|
Respiratory Function Tests | 1 | 2006 | 1682 | 0.010 |
Why?
|
Point Mutation | 1 | 2006 | 1595 | 0.010 |
Why?
|
Glucocorticoids | 1 | 2010 | 2161 | 0.010 |
Why?
|
Cross-Sectional Studies | 2 | 2014 | 26125 | 0.010 |
Why?
|
Genetic Testing | 1 | 2014 | 3537 | 0.010 |
Why?
|
Exercise Tolerance | 1 | 2006 | 836 | 0.010 |
Why?
|
Phosphoproteins | 1 | 2009 | 2448 | 0.010 |
Why?
|
Parents | 1 | 2014 | 3563 | 0.010 |
Why?
|
Leukocyte Count | 1 | 2004 | 1596 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2010 | 6075 | 0.010 |
Why?
|
Exons | 1 | 2006 | 2391 | 0.010 |
Why?
|
Activities of Daily Living | 1 | 2009 | 2421 | 0.010 |
Why?
|
Erythropoietin | 1 | 2004 | 719 | 0.010 |
Why?
|
Disease Models, Animal | 2 | 2009 | 18252 | 0.010 |
Why?
|
Cell Movement | 1 | 2011 | 5203 | 0.010 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2009 | 2872 | 0.010 |
Why?
|
Health Surveys | 1 | 2009 | 4061 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2010 | 4740 | 0.010 |
Why?
|
Kidney Diseases | 1 | 1990 | 2091 | 0.010 |
Why?
|
Receptor, erbB-2 | 1 | 2009 | 2557 | 0.010 |
Why?
|
Cell Cycle | 1 | 2007 | 2932 | 0.010 |
Why?
|
Nerve Tissue Proteins | 1 | 2011 | 4414 | 0.010 |
Why?
|
Contrast Media | 1 | 2012 | 5311 | 0.010 |
Why?
|
NF-kappa B | 1 | 2007 | 2490 | 0.010 |
Why?
|
Thymus Gland | 1 | 2003 | 1243 | 0.010 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2009 | 3492 | 0.010 |
Why?
|
Blood Platelets | 1 | 2009 | 2479 | 0.010 |
Why?
|
Cell Cycle Proteins | 1 | 2009 | 3448 | 0.010 |
Why?
|
Massachusetts | 1 | 2011 | 8830 | 0.010 |
Why?
|
RNA Interference | 1 | 2006 | 2831 | 0.010 |
Why?
|
HLA Antigens | 1 | 2003 | 1328 | 0.010 |
Why?
|
DNA Methylation | 1 | 2012 | 4398 | 0.010 |
Why?
|
DNA Repair | 1 | 2007 | 2045 | 0.010 |
Why?
|
Surgical Wound Infection | 1 | 2007 | 1527 | 0.010 |
Why?
|
RNA | 1 | 2007 | 2726 | 0.010 |
Why?
|
Virus Diseases | 1 | 2003 | 718 | 0.010 |
Why?
|
Kidney | 2 | 2009 | 7048 | 0.010 |
Why?
|
Disease Susceptibility | 1 | 2003 | 1787 | 0.010 |
Why?
|
Prevalence | 1 | 2013 | 15732 | 0.010 |
Why?
|
Tamoxifen | 1 | 2001 | 965 | 0.010 |
Why?
|
Neutrophils | 1 | 2009 | 3767 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2016 | 36426 | 0.010 |
Why?
|
Chronic Disease | 1 | 2010 | 9318 | 0.010 |
Why?
|
Stroke | 1 | 2017 | 9757 | 0.010 |
Why?
|
Computer Simulation | 1 | 2008 | 6240 | 0.010 |
Why?
|
Comorbidity | 1 | 2009 | 10508 | 0.010 |
Why?
|
Phenotype | 1 | 2012 | 16591 | 0.010 |
Why?
|
Models, Biological | 1 | 2010 | 9469 | 0.010 |
Why?
|
Obesity | 1 | 2015 | 12947 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2007 | 7594 | 0.010 |
Why?
|
Receptors, GABA | 1 | 1995 | 313 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2013 | 26198 | 0.010 |
Why?
|
Hemorrhage | 1 | 2004 | 3424 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2010 | 11528 | 0.010 |
Why?
|
Pyridoxine | 1 | 1992 | 108 | 0.010 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2006 | 3204 | 0.010 |
Why?
|
Health Status | 1 | 2004 | 4077 | 0.010 |
Why?
|
Erythrocyte Aging | 1 | 1990 | 53 | 0.010 |
Why?
|
Actuarial Analysis | 1 | 1990 | 372 | 0.010 |
Why?
|
Thromboembolism | 1 | 1996 | 995 | 0.010 |
Why?
|
Cross-Over Studies | 1 | 1996 | 2078 | 0.010 |
Why?
|
Hemolytic-Uremic Syndrome | 1 | 1990 | 106 | 0.010 |
Why?
|
Splenomegaly | 1 | 1990 | 189 | 0.010 |
Why?
|
Lymphography | 1 | 1990 | 188 | 0.010 |
Why?
|
Multiple Myeloma | 1 | 2007 | 5146 | 0.010 |
Why?
|
Hair Color | 1 | 1989 | 131 | 0.000 |
Why?
|
Mice, Inbred C3H | 1 | 1990 | 915 | 0.000 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 1993 | 1148 | 0.000 |
Why?
|
Kidney Glomerulus | 1 | 1990 | 568 | 0.000 |
Why?
|
Laparotomy | 1 | 1990 | 457 | 0.000 |
Why?
|
Drug Resistance | 1 | 1993 | 1596 | 0.000 |
Why?
|
Hemolysis | 1 | 1989 | 415 | 0.000 |
Why?
|
Estrogens | 1 | 1993 | 1522 | 0.000 |
Why?
|
Prednisone | 1 | 1991 | 1563 | 0.000 |
Why?
|
Erythropoiesis | 1 | 1990 | 683 | 0.000 |
Why?
|
Thrombocytopenia | 1 | 1994 | 1181 | 0.000 |
Why?
|
Random Allocation | 1 | 1990 | 2395 | 0.000 |
Why?
|
Central Nervous System Diseases | 1 | 1990 | 520 | 0.000 |
Why?
|
Death, Sudden, Cardiac | 1 | 1993 | 1555 | 0.000 |
Why?
|
Cataract | 1 | 1989 | 832 | 0.000 |
Why?
|
Double-Blind Method | 1 | 1996 | 12341 | 0.000 |
Why?
|
Hematopoiesis | 1 | 1989 | 2049 | 0.000 |
Why?
|
Calcium | 1 | 1991 | 5722 | 0.000 |
Why?
|
Weight Loss | 1 | 1989 | 2684 | 0.000 |
Why?
|
Myocardial Infarction | 1 | 1993 | 11460 | 0.000 |
Why?
|
Cardiovascular Diseases | 1 | 1996 | 15500 | 0.000 |
Why?
|